导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.19% | 1670/4773 |
| 近一周 | 0.08% | 824/5465 |
| 近一月 | -2.68% | 1818/5421 |
| 近一季 | -4.42% | 1815/5231 |
| 近半年 | -4.42% | 2821/4920 |
| 近一年 | 8.91% | 1263/4394 |
| 近两年 | 75.38% | 917/2954 |
| 近三年 | 43.13% | 690/2253 |
| 成立以来 | 65.60% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.85% 1432/4961 |
9.03% 2508/5312 |
- - |
- - |
| 2025 | 34.77% 1022/4813 |
3.80% 1037/3635 |
1.77% 2156/4076 |
24.85% 1428/4524 |
2.17% 1061/4813 |
| 2024 | 7.95% 1600/3463 |
-0.77% 1142/2808 |
-3.95% 1441/3014 |
12.15% 2405/3129 |
0.99% 1140/3463 |
| 2023 | -2.13% 558/2656 |
8.12% 492/2280 |
-2.94% 717/2385 |
-2.65% 712/2515 |
-4.20% 908/2655 |
| 2022 | -16.53% 489/2207 |
-10.04% 374/1919 |
4.51% 1007/2016 |
-11.60% 549/2113 |
0.43% 1494/2208 |
| 2021 | -0.81% 761/1822 |
-1.14% 438/1255 |
10.43% 462/1330 |
0.07% 472/1466 |
-9.20% 1595/1822 |
| 2020 | 20.68% 709/1250 |
-4.69% 378/1028 |
19.24% 305/1067 |
5.60% 905/1164 |
0.55% 1055/1184 |
| 2019 | 28.93% 512/1092 |
19.68% 623/739 |
4.68% 20/788 |
-1.48% 659/850 |
4.46% 800/918 |
| 2018 | -20.76% 199/834 |
- - |
-10.11% 301/631 |
-4.87% 350/660 |
-7.74% 70/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国泰中证500指数增强A VS. 长安沪深300非周期A(740101) |